Skip to Content

Becton Dickinson & Co

BDX: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$174.00ByhsvDpqsckvdc

Becton, Dickinson's Core Business on Solid Trajectory

Business Strategy and Outlook

After a tumultous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm's core business growth in the upcoming years once the testing revenue fades. The biggest uncertainty remains around the return of BD's pump infusion system (Alaris) to the market, which could be a material catalyst for the company whenever it occurs.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BDX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center